vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FB Financial Corp (FBK). Click either name above to swap in a different company.

FB Financial Corp is the larger business by last-quarter revenue ($178.6M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 37.0%). Over the past eight quarters, FB Financial Corp's revenue compounded faster (28.9% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Fubon Financial Holding Co., Ltd. is a financial investment holding company consists of the following key subsidiaries: Fubon Asset Management, Fubon Insurance Co. Ltd., Fubon Securities, Fubon Bank, Fubon Life, Fubon Bank (China) and Fubon Bank Limited. The holding company was setup on 19 December 2001.

ESPR vs FBK — Head-to-Head

Bigger by revenue
FBK
FBK
1.1× larger
FBK
$178.6M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+106.7% gap
ESPR
143.7%
37.0%
FBK
Faster 2-yr revenue CAGR
FBK
FBK
Annualised
FBK
28.9%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
FBK
FBK
Revenue
$168.4M
$178.6M
Net Profit
$57.0M
Gross Margin
Operating Margin
50.6%
39.1%
Net Margin
31.9%
Revenue YoY
143.7%
37.0%
Net Profit YoY
50.4%
EPS (diluted)
$0.32
$1.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
FBK
FBK
Q4 25
$168.4M
$178.6M
Q3 25
$87.3M
$173.9M
Q2 25
$82.4M
$76.9M
Q1 25
$65.0M
$130.7M
Q4 24
$69.1M
$130.4M
Q3 24
$51.6M
$89.5M
Q2 24
$73.8M
$128.2M
Q1 24
$137.7M
$107.5M
Net Profit
ESPR
ESPR
FBK
FBK
Q4 25
$57.0M
Q3 25
$-31.3M
$23.4M
Q2 25
$-12.7M
$2.9M
Q1 25
$-40.5M
$39.4M
Q4 24
$37.9M
Q3 24
$-29.5M
$10.2M
Q2 24
$-61.9M
$40.0M
Q1 24
$61.0M
$27.9M
Operating Margin
ESPR
ESPR
FBK
FBK
Q4 25
50.6%
39.1%
Q3 25
-11.4%
17.0%
Q2 25
8.6%
-12.7%
Q1 25
-34.0%
37.4%
Q4 24
-6.4%
38.4%
Q3 24
-31.0%
12.7%
Q2 24
3.5%
39.7%
Q1 24
52.5%
31.9%
Net Margin
ESPR
ESPR
FBK
FBK
Q4 25
31.9%
Q3 25
-35.9%
13.4%
Q2 25
-15.4%
3.8%
Q1 25
-62.2%
30.1%
Q4 24
29.1%
Q3 24
-57.2%
11.4%
Q2 24
-83.9%
31.2%
Q1 24
44.3%
26.0%
EPS (diluted)
ESPR
ESPR
FBK
FBK
Q4 25
$0.32
$1.12
Q3 25
$-0.16
$0.43
Q2 25
$-0.06
$0.06
Q1 25
$-0.21
$0.84
Q4 24
$-0.14
$0.82
Q3 24
$-0.15
$0.22
Q2 24
$-0.33
$0.85
Q1 24
$0.34
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
FBK
FBK
Cash + ST InvestmentsLiquidity on hand
$167.9M
$1.2B
Total DebtLower is stronger
$212.8M
Stockholders' EquityBook value
$-302.0M
$1.9B
Total Assets
$465.9M
$16.3B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
FBK
FBK
Q4 25
$167.9M
$1.2B
Q3 25
$92.4M
$1.3B
Q2 25
$86.1M
$1.2B
Q1 25
$114.6M
$794.7M
Q4 24
$144.8M
$1.0B
Q3 24
$144.7M
$951.8M
Q2 24
$189.3M
$800.9M
Q1 24
$226.6M
$870.7M
Total Debt
ESPR
ESPR
FBK
FBK
Q4 25
$212.8M
Q3 25
$213.6M
Q2 25
Q1 25
Q4 24
$176.8M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ESPR
ESPR
FBK
FBK
Q4 25
$-302.0M
$1.9B
Q3 25
$-451.4M
$2.0B
Q2 25
$-433.5M
$1.6B
Q1 25
$-426.2M
$1.6B
Q4 24
$-388.7M
$1.6B
Q3 24
$-370.2M
$1.6B
Q2 24
$-344.2M
$1.5B
Q1 24
$-294.3M
$1.5B
Total Assets
ESPR
ESPR
FBK
FBK
Q4 25
$465.9M
$16.3B
Q3 25
$364.0M
$16.2B
Q2 25
$347.1M
$13.4B
Q1 25
$324.0M
$13.1B
Q4 24
$343.8M
$13.2B
Q3 24
$314.1M
$12.9B
Q2 24
$352.3M
$12.5B
Q1 24
$373.1M
$12.5B
Debt / Equity
ESPR
ESPR
FBK
FBK
Q4 25
0.11×
Q3 25
0.11×
Q2 25
Q1 25
Q4 24
0.11×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
FBK
FBK
Operating Cash FlowLast quarter
$45.2M
$155.9M
Free Cash FlowOCF − Capex
$147.0M
FCF MarginFCF / Revenue
82.3%
Capex IntensityCapex / Revenue
0.0%
5.0%
Cash ConversionOCF / Net Profit
2.74×
TTM Free Cash FlowTrailing 4 quarters
$242.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
FBK
FBK
Q4 25
$45.2M
$155.9M
Q3 25
$-4.3M
$47.7M
Q2 25
$-31.4M
$71.8M
Q1 25
$-22.6M
$-16.5M
Q4 24
$-35.0M
$138.8M
Q3 24
$-35.3M
$57.8M
Q2 24
$-7.2M
$30.6M
Q1 24
$53.8M
$36.3M
Free Cash Flow
ESPR
ESPR
FBK
FBK
Q4 25
$147.0M
Q3 25
$45.6M
Q2 25
$68.4M
Q1 25
$-18.1M
Q4 24
$132.3M
Q3 24
$-35.5M
$56.7M
Q2 24
$-7.3M
$28.4M
Q1 24
$53.8M
$34.6M
FCF Margin
ESPR
ESPR
FBK
FBK
Q4 25
82.3%
Q3 25
26.2%
Q2 25
89.0%
Q1 25
-13.9%
Q4 24
101.4%
Q3 24
-68.7%
63.3%
Q2 24
-9.9%
22.1%
Q1 24
39.0%
32.2%
Capex Intensity
ESPR
ESPR
FBK
FBK
Q4 25
0.0%
5.0%
Q3 25
0.0%
1.2%
Q2 25
0.0%
4.4%
Q1 25
0.0%
1.3%
Q4 24
0.0%
5.0%
Q3 24
0.3%
1.2%
Q2 24
0.1%
1.7%
Q1 24
0.1%
1.5%
Cash Conversion
ESPR
ESPR
FBK
FBK
Q4 25
2.74×
Q3 25
2.04×
Q2 25
24.68×
Q1 25
-0.42×
Q4 24
3.66×
Q3 24
5.65×
Q2 24
0.77×
Q1 24
0.88×
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

FBK
FBK

Segment breakdown not available.

Related Comparisons